CJC-1295 DAC (2mg Vial) Dosage Protocol

CJC-1295 DAC (2 mg Vial) Dosage Protocol

Quickstart Highlights

CJC-1295 DAC (2 mg Vial) is a long-acting GHRH analog that forms an albumin bond in vivo, extending its half-life to ~6–8 days and enabling once-weekly research dosing schedules. This page provides an educational reconstitution and dosing unit guide for a 2 mg vial.

  • Reconstitute: 1.0 mL bacteriostatic water → 2 mg/mL (2,000 mcg/mL)
  • Once-weekly schedule supported by pharmacokinetics (t½ ≈ 6–8 days)
  • Standard approach: 1.0 mg (50 units / 0.50 mL) once weekly
  • Advanced approach: 2.0 mg (100 units / 1.00 mL) once weekly
  • Storage: Lyophilized frozen; reconstituted refrigerated (details below)

Product ID: 1043

CJC-1295 DAC 2 mg Vial

Dosing & Reconstitution Guide

Educational guide for reconstitution and dosing units

Reconstitution (1.0 mL = 2 mg/mL)

  1. Draw 1.0 mL of bacteriostatic water (0.9% benzyl alcohol) into a sterile syringe.
  2. Inject slowly down the vial wall; gently swirl (avoid vigorous shaking).
  3. Label the vial with date and concentration (2 mg/mL).
  4. Refrigerate reconstituted solution at 2–8 °C (36–46 °F), protected from light.

Why 1.0 mL? It yields practical once-weekly injection volumes (≤1.0 mL). Using larger volumes (e.g., 2–3 mL) would increase “units” but may require >1 mL per injection at higher weekly doses. Do not exceed 3 mL per vial.

Standard / Gradual Approach (1.0 mL = 2 mg/mL)

Week(s) Weekly Dosage Units (mL) per Injection
Weeks 1–8 1.0 mg once weekly 50 units (0.50 mL)

Frequency: Inject 1× per week subcutaneously. One 2 mg vial provides two 1 mg injections (≈2 weeks).

Advanced / Aggressive Approach (1.0 mL = 2 mg/mL)

Week(s) Weekly Dosage Units (mL) per Injection
Weeks 1–8 2.0 mg once weekly 100 units (1.00 mL)

Frequency: Inject 1× per week subcutaneously. One 2 mg vial provides one 2 mg injection (≈1 week).

Tip: If your syringes are <1 mL capacity, split the 2.0 mg dose into two back-to-back injections to maintain accuracy.

Notes: The once-weekly pattern is based on the extended half-life and sustained IGF-1 response reported in human studies. This guide shows unit math for a 2 mg vial; always align with your approved research protocol.

Supplies Needed

Estimates for 8–16 week research cycles.

  • Peptide Vials (2 mg each):
    • Standard 1 mg/wk → 8 wks ≈ 4 vials; 12 wks ≈ 6; 16 wks ≈ 8
    • Advanced 2 mg/wk → 8 wks ≈ 8 vials; 12 wks ≈ 12; 16 wks ≈ 16
  • Insulin Syringes: 8 / 12 / 16 (match weekly injections)
  • Bacteriostatic Water: 10 mL bottle(s): 8–12 wks = 1×; 16 wks (advanced) = 2×
  • Alcohol Swabs: 1 box
CJC-1295 DAC (supplier)
View Supplier
Insulin Syringes
View Supplier
Bacteriostatic Water
View Supplier
Alcohol Pads
View Supplier

Protocol Overview

  • Goal (research): Model GH/IGF-1 axis stimulation using a long-acting GHRH analog
  • Schedule: Once weekly subcutaneous dosing for 8–12 weeks (extendable per protocol)
  • Dose Range: 1.0–2.0 mg weekly (see unit tables above)
  • Reconstitution: 1.0 mL → 2 mg/mL; practical 25–100 insulin units per injection
  • Storage: Lyophilized frozen; reconstituted refrigerated (details below)

Dosing Protocol

  • Standard: 1.0 mg (50 units / 0.50 mL) once weekly
  • Advanced: 2.0 mg (100 units / 1.00 mL) once weekly
  • Timing: Any consistent weekly time; separate from meals if specified by your protocol
  • Documentation: Record lot, concentration, date/time, site, and volume for each injection

Storage Instructions

  • Lyophilized: Freeze for long-term storage (≤ −20 °C / −4 °F ideally); short-term at 2–8 °C / 36–46 °F.
  • Reconstituted: Refrigerate at 2–8 °C / 36–46 °F; avoid repeated freeze–thaw; aliquot if needed.
  • Allow the vial to reach room temp before opening to reduce moisture uptake; protect from light.

Important Notes

  • Use new, sterile syringes; do not reuse needles or share multi-dose vials between subjects.
  • Rotate injection sites (abdomen, thigh, etc.) and clean the stopper and skin with alcohol.
  • Monitor and document observations; discontinue per protocol if unexpected reactions occur.
  • Research Use Only: Not for human or veterinary use. This page is for educational purposes only.

How This Works

CJC-1295 DAC is a modified GHRH(1-29) analog that bioconjugates to albumin (Cys-34), prolonging circulation time. In healthy adults, single doses produced 2–10× GH increases for ~6 days and IGF-1 elevation for ~9–11 days; multiple doses sustained IGF-1 above baseline for up to 28 days, while preserving GH pulsatility.

Potential Observations in Research

  • Intended effect: Dose-dependent increases in GH and IGF-1
  • Commonly reported events: Injection-site reactions, flushing, headache, transient nausea
  • Metabolic caution: GH axis activation can influence glucose/insulin dynamics; monitor per protocol

Lab & Handling Practices

  • Standardize dosing day/time and records to improve dataset quality.
  • Use validated measuring devices; verify syringe calibration when feasible.
  • Follow sterile handling and USP <797> principles when preparing sterile preparations.

Injection Technique (Educational)

  • Use aseptic technique; a new needle & syringe for each injection.
  • Subcutaneous angle: 45–90°, inject slowly; dispose in sharps container.
  • Do not exceed syringe capacity; split doses if volume > 1 mL.

Compliance Notice

For Research Use Only.